Related Experiment Video
Updated: Mar 16, 2026
Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
Proteome-wide antigen discovery of novel protective vaccine candidates against Staphylococcus aureus infection
Karina Juhl Rasmussen1, Andreas Holm Mattsson2, Katrine Pilely1
1Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark.
Abstract:
Methicillin-resistant Staphylococcus aureus (MRSA) is a rapidly growing problem, especially in hospitals where MRSA cause increased morbidity and mortality and a significant rise in health expenditures. As many strains of MRSA are resistant to other antimicrobials in addition to methicillin, there is an urgent need to institute non-antimicrobial measures, such as vaccination, against the spread of MRSA. With the aim of finding new protective antigens for vaccine development, this study used a proteome-wide in silico antigen prediction platform to screen the proteome of S. aureus strain MRSA252. Thirty-five different S. aureus proteins were identified, recombinantly expressed, and tested for protection in a lethal sepsis mouse model using S. aureus strain MRSA252 as the challenge organism. We found that 13 of the 35 recombinant peptides yielded significant protection and that 12 of these antigens were highly conserved across 70 completely sequenced S. aureus strains. Thus, this in silico platform was capable of identifying novel candidates for inclusion in future vaccines against MRSA.
Insights
This study identified 13 protective antigens from Methicillin-resistant Staphylococcus aureus (MRSA) using an in silico platform. These findings offer promising candidates for developing new vaccines against MRSA infections.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat in healthcare settings, causing increased illness, death, and healthcare costs.
- The rise in antimicrobial resistance necessitates non-antimicrobial strategies, such as vaccines, to combat MRSA spread.
Purpose of the Study:
- To identify novel protective antigens for MRSA vaccine development.
- To screen the S. aureus proteome using an in silico antigen prediction platform.
Main Methods:
- Utilized a proteome-wide in silico antigen prediction platform to analyze S. aureus strain MRSA252.
- Recombinantly expressed 35 identified S. aureus proteins.
- Evaluated protective efficacy in a lethal sepsis mouse model challenged with S. aureus MRSA252.
Main Results:
- Identified 35 potential S. aureus protein antigens.
- 13 of the 35 recombinant peptides demonstrated significant protection against MRSA challenge.
- 12 of the protective antigens were highly conserved across 70 sequenced S. aureus strains.
Conclusions:
- The in silico antigen prediction platform effectively identified novel vaccine candidates.
- The identified conserved antigens represent promising targets for future MRSA vaccines.
- This approach can accelerate the development of effective non-antimicrobial strategies against MRSA.
Related Concept Videos
01:31Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
01:26Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and...